The pharmaceutical industry in the UK is currently involved in a limited number of traditional Framework (FP7) projects. Pharmaceutical companies are, however, fully engaged in collaborations that are being established through the Innovative Medicines Initiative (IMI) – one of the Joint Technology Initiatives (JTIs) established under Framework 7. The ABPI and its member companies are members of EFPIA, which, with the European Commission, was the founding member of IMI. The great majority of UK pharmaceutical industry involvement in FP7 is via IMI.
We believe that the UK’s high level objectives for FP8 should be to leverage benefit from European research to drive innovation and support key industry sectors, including pharmaceuticals and the SME biopharmaceutical community. The UK should seek to strengthen the UK’s core competencies in areas such as biomedical research, as well as supporting and developing the associated science skills base across the whole of the EU. The UK should consider FP8 as providing an opportunity to enhance collaboration between companies, academics and regulators, stimulating data-sharing and problem-solving activities across key sectors.
The European pharmaceutical industry sought to establish IMI as a mechanism to help overcome bottlenecks in pharmaceutical R&D and to enhance access to a mobile talent pool, as it considered existing Framework mechanisms were too complex, administratively time-consuming and bureaucratic. There is still a number of significant issues that need to be addressed concerning the management of FP programmes, including JTIs such as IMI. Simplification of FP must remain a high level objective.
Download the EU Framework Programme – ABPI response (PDF, 211KB)